NCT06635902

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

A Phase 2 Randomized Double-blind, Placebo-controlled Clinical Trial of Intravenous Citrulline for Vaso-occlusive Pain Episode in Hospitalized Patients With Sickle Cell Disease (CONQUER SCD Pain Trial)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (estimated)
• Sponsor: Suvankar Majumdar · Academic / Other
• Sex: All
• Age: 4 Years – 21 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are: * Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain. Participants will: * Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay * After hospital discharge, visit the clinic in about 30 days for checkup and tests

Detailed description

This is a single-center phase 2 randomized double-blind, placebo-controlled trial of intravenous L-citrulline for sickle cell patients ages 4 to 21 years experiencing a vaso-occlusive pain crisis episode (VOE). Eligible subjects will have a documented history of sickle cell disease and inpatient hospitalization for treatment of acute pain with parenteral opioid. Subjects will be randomized to receive high dose intravenous L-citrulline, low dose intravenous L-citrulline or placebo in addition to standard of care. Subjects will be followed closely to evaluate time-to-crisis resolution as the primary outcome defined by time from first dose of intravenous study drug/placebo to the last dose of parenteral opioid prior to hospital discharge. Participants will be monitored for any adverse events including 30-day re-hospitalization rates. Total opioid consumption during the time-to-crisis resolution will be compared between the three arms. In addition, exploratory outcomes will be evaluated for pain score, tissue blood flow, genetic and candidate biomarkers related to vaso-occlusion. Objectives Primary Objective • To demonstrate the efficacy of intravenous L-citrulline in reducing the time-to-crisis resolution in sickle cell subjects experiencing a vaso-occlusive pain crisis episode (VOE). Secondary Objectives * To evaluate the safety of intravenous L-citrulline in the treatment of VOE * To determine if intravenous L-citrulline improves cumulative opioid consumption during the treatment of VOE Exploratory Objectives * To determine if intravenous L-citrulline improves pain scores during the hospitalization * To determine if intravenous L-citrulline improves 30-day re-hospitalization rates * To determine the pharmacokinetic (PK) profile of intravenous L-citrulline * To evaluate whether intravenous L-citrulline improves tissue blood flow and candidate biomarkers related to vaso-occlusion. * To assess whether genetic single nucleotide polymorphisms related to the nitric oxide pathway influence study outcomes

Conditions

• Sickle Cell Disease
• Vaso-occlusive Pain Episode

Interventions

Type	Name	Description
DRUG	L-citrulline	Intravenous L-citrulline (50 mg/kg + 9mg/kg/hr.) for 16 hours
OTHER	Placebo	Isotonic normal saline
DRUG	L-citrulline	Intravenous L-citrulline (25 mg/kg + 9mg/kg/hr.) for 16 hours

Timeline

• Start date: 2024-12-22
• Primary completion: 2028-06-01
• Completion: 2029-03-01
• First posted: 2024-10-10
• Last updated: 2026-04-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study